Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers
Authors:
Open Access
- 12 October 2017
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 9 (1) , 59-65
Abstract
Background: The purpose of this retrospective study was to evaluate the feasibility and efficacy of definitive concurrent chemoradiotherapy (CCRT) with capecitabine and cisplatin for elderly patients with locally advanced esophageal squamous cell carcinoma.Methods: A total of 90 patients were included from two different centers. Forty‐nine patients were treated with CCRT consisting of capecitabine (850 mg/m2, oral, twice a day for 1–14 days) and cisplatin (20 mg/m2) weekly during radiotherapy (RT). The remaining 41 patients were treated with RT alone. The overall response, overall survival, progression‐free survival, and toxicity rates were recorded.Results: Compared to the RT group (51.2%; P = 0.029), the overall response rate in the CCRT group (73.5%) was obviously higher. A complete response was achieved in 34.7% and 14.6% of patients in the CCRT and RT groups, respectively (P = 0.030). Median progression‐free and median overall survival rates were significantly higher in the CCRT group (24.7 and 30.6 months; P < 0.05) compared to the RT group (16.6 and 18.7 months). Acute toxic effects were more severe in the CCRT group, but no significant difference in grade 3 or 4 acute toxicities was observed between the groups.Conclusion: Both CCRT with capecitabine and cisplatin and RT alone are feasible to treat elderly patients and yield a good performance status with locally advanced esophageal squamous cell carcinoma. CCRT improved the tumor response without increasing the side effects compared to RT alone. CCRT is recommended for patients over 65 with good performance status.Keywords
Funding Information
- National Natural Science Foundation of China (81672974)
This publication has 27 references indexed in Scilit:
- Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancerJournal of Cancer Research and Clinical Oncology, 2014
- Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up dataCancer Chemotherapy and Pharmacology, 2011
- Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinomaRadiotherapy and Oncology, 2009
- A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501)Radiotherapy and Oncology, 2008
- A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinomaCancer Chemotherapy and Pharmacology, 2007
- Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.Clinical and Translational Oncology, 2007
- A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignanciesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemotherapy and Pharmacology, 2000
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- Tumor Selective Delivery of 5-Fluorouracil by Capecitabine, a New Oral Fluoropyrimidine Carbamate, in Human Cancer XenograftsBiochemical Pharmacology, 1998